NCT03252600View on ClinicalTrials.gov

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

PHASE2UnknownINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 25, 2017

Primary Completion Date

December 7, 2023

Study Completion Date

December 7, 2023

Conditions
Recurrent Primary Amyloidosis
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Dexamethasone

Given IV

BIOLOGICAL

Elotuzumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (5)

28204

Levine Cancer Center, Charlotte

30322

Emory Winship Cancer Institute, Atlanta

48201

Wayne State University/Karmanos Cancer Institute, Detroit

80218

Colorado Blood Cancer, Denver

91010

City of Hope Comprehensive Cancer Center, Duarte

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

lead

Barbara Ann Karmanos Cancer Institute

OTHER